VCIM
PNT

Velan Capital Investment Management’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

Velan Capital Investment Management’s Portfolio PNT Stock Details PNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-342,936
Closed -$3.11M – 36
2023
Q2 		$3.11M Sell
342,936
-151,200
-31% -$1.33M 2.88% 14
2023
Q1 		$3.59M Hold
494,136
– – 3.06% 11
2022
Q4 		$3.6M Buy
+494,136
New +$3.67M 3.18% 10

Other funds holding PNT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Velan Capital Investment Management's PNT Position: Q3 2023 in Review

Velan Capital Investment Management sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q3 2023, closing a stake of 342,936 shares — an estimated $3.11M sold.

Velan Capital Investment Management first reported a position in PNT in Q4 2022 and held it in 3 quarters. The position peaked at $3.6M in Q4 2022. 125 funds tracked by Wall St. Rank hold PNT as of Q3 2023.

  • Velan Capital Investment Management reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Velan Capital Investment Management sold 342,936 POINT Biopharma Global Inc. Common Stock shares in Q3 2023, an estimated $3.11M.
  • Velan Capital Investment Management first reported a position in POINT Biopharma Global Inc. Common Stock in Q4 2022 and held it in 3 quarters.
  • Velan Capital Investment Management's POINT Biopharma Global Inc. Common Stock position peaked at $3.6M in Q4 2022.
  • 125 funds tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q3 2023.

Based on Velan Capital Investment Management's 13F filing for Q3 2023, filed 13 Nov 2023.